Skip to main content
SpringerLink
Log in

Immunotherapy with tumor cell subpopulations

III. Interaction between specific and nonspecific immunostimulants

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

The use of isolated tumor cell subpopulations combined with nonspecific immunostimulation (BCG and C parvum) was studied in the L1210-B6D2F1 tumor-host model. Some tumor cell vaccines abrogated the immunotherapeutic value of nonspecific immunostimulants. A tumor cell vaccine prepared from a subpopulation with no apparent immunotherapeutic value completely neutralized the excellent therapeutic value of C parvum in this tumor-host model. The results emphasize the limitations of immunotherapy, and also the need to understand fundamental relationships between the immunological status of the host and subsequent immune stimulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bekesi, J. G., St. Arneault, G., Holland, J. F.: Increase of leukemia L1210 immunogenicity by Vibrio cholerae neuraminidase treatment. Cancer Res. 31, 2130–2136 (1971)

    Google Scholar 

  • Carter, S. K.: The current status of clinical immunotherapy as viewed at the 1976 AACR-ASCO meetings. Cancer Immunol. Immunother. 1, 275–281 (1976)

    Google Scholar 

  • Currie, G. A., Bagshawe, K. D.: The role of sialic acid in antigenic expression: Further studies of the landschutz ascites tumor. Br. J. Cancer 22, 843–847 (1968)

    Google Scholar 

  • Fidler, I. J.: Selection of successive tumor lines for metastasis. Nature 242, 148–149 (1973)

    Google Scholar 

  • Gutterman, J. U.: Cancer systemic active immunotherapy today — Prospects for tomorrow. Cancer Immunol. Immunother. 2, 1–9 (1977)

    Google Scholar 

  • Gutterman, J. U., Mavligit, G. M., Burgess, M. A., et al.: Immunotherapy of breast cancer, malignant melanoma, and acute leukemia with BCG: Prolongation of disease-free interval and survival. Cancer Immunol. Immunother. 1, 99–107 (1976)

    Google Scholar 

  • Hersh, E. M., Gutterman, J. U., Mavligit, G.: Immunotherapy of Cancer in man. Springfield, Ill.: Charles C. Thomas 1973

    Google Scholar 

  • Jacobs, D. M., Kripke, M. L.: Accelerated development of transplanted mammary tumors in mice pretreated with the methanol extraction residue of BCG and prevention of acceleration by concomitant specific immunization. J. Natl. Cancer Inst. 52, 219–224 (1974)

    Google Scholar 

  • Killion, J. J.: Reduced tumorigenicity of A-10 adenocarcinoma in the presence of immunogenic A-10 tumor cells. Cancer Immunol. Immunother. 3, 93–95 (1977a)

    Google Scholar 

  • Killion, J. J.: The immunotherapeutic value of a L1210 tumor cell vaccine depends upon the expression of cell-surface carbohydrates. Cancer Immunol. Immunother. 3, 87–91 (1977b)

    Google Scholar 

  • Killion, J. J.: Immunotherapy with tumor cell subpopulations. I. Active, specific immunotherapy of L1210 leukemia. Cancer Immunol. Immunother. 4, 115–119 (1978a)

    Google Scholar 

  • Killion, J. J.: Immunotherapy with tumor cell subpopulations. II. Therapy of drug-resistant L1210 leukemia and EL4 lymphoma. Cancer Immunol. Immunother. 5, 21–26 (1978b)

    Google Scholar 

  • Killion, J. J., Kollmorgen, G. M.: Isolation of immunogenic tumor cells by cell affinity chromatography. Nature 259, 674–676 (1976)

    CAS  PubMed  Google Scholar 

  • Killion, J. J., Wallenbrock, M. A., Rogers, J. A., et al.: Tumorigenicity and the expression of cell-surface carbohydrates. Nature 261, 54–56 (1976)

    CAS  PubMed  Google Scholar 

  • Killion, J. J., Wallenbrock, M. A., Kollmorgen, G. M., et al.: Properties of tumor cell vaccines. Cancer Res. 18, 54a (1977)

  • LeFever, A. V., Killion, J. J., Kollmorgen, G. M.: Active immunotherapy of L1210 leukemia with neuraminidase-treated, drug-resistant L1210 sublines. Cancer Immunol. Immunother. 1, 211–217 (1976)

    Google Scholar 

  • Martin, W. J., Wunderlich, J. R., Fletcher, F., et al.: Enhanced immugenicity of chemically-coated syngeneic tumor cells. Proc. Natl. Acad. Sci. 68, 469–472 (1971)

    Google Scholar 

  • Mihich, E., Kitano, M.: Differences in the immunogenicity of leukemia L1210 sublines in DBA/2 mice. Cancer Res. 31, 1999–2010 (1971)

    Google Scholar 

  • Nicolin, A., Vadlamudi, S., Goldin, A.: Antigenicity of L1210 leukemia sublines induced by drugs. Cancer Res. 32, 653–660 (1972)

    Google Scholar 

  • Powles, R. L., Selby, P. J., Jones, D. R., Russell, J. A., Prentice, H. G., McElwain, T. J., Alexander, P.: Maintenance of remission in acute myelogenous leukemia by a mixture of BCG and irradiated leukemia cells. Lancet 1977 2, 1107–1109

    Google Scholar 

  • Prager, M. D., Derr, I., Swann, A., et al.: Immunization with chemically modified lymphoma cells. Cancer Res. 31, 1488–1492 (1971)

    Google Scholar 

  • Sanford, B. H., Codington, J. F.: Further studies on the effect of neuraminidase on tumor cell transplantability. Tissue Antigens 1, 153–156 (1971)

    Google Scholar 

  • Simmons, R. L., Rios, A. J.: Immunotherapy of cancer: Immunospecific rejection of tumors in recipients of neuraminidase-treated cells plus BCG. Science 174, 591–595 (1971)

    Google Scholar 

  • Simmons, R. L., Rios, A. J.: Cell surface modification in the treatment of experimental cancer: Neuraminidase or concanavalin A. Cancer 34, 1541–1546 (1974)

    Google Scholar 

  • Wallenbrock, M. A., Killion, J. J.: Isolation of high-rate DNA synthetic cells by con A chromatography. J. Cell. Physiol. 95, 151–158 (1978)

    Google Scholar 

Download references

Author information

Author notes

  1. Jerald J. Killion

    Present address: Department of Physiology, Oral Roberts University, School of Medicine, 7777 S. Lewis Avenue, 74171, Tulsa, Oklahoma, USA

Authors and Affiliations

  1. Cancer Research Program, Oklahoma Medical Research Foundation, USA

    Jerald J. Killion

  2. Department of Radiological Sciences, University of Oklahoma Health Sciences Center, 825 N.E. 13th Street, 73104, Oklahoma City, Oklahoma, USA

    Jerald J. Killion

Authors
  1. Jerald J. Killion
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Killion, J.J. Immunotherapy with tumor cell subpopulations. Cancer Immunol Immunother 5, 27–30 (1978). https://doi.org/10.1007/BF00199204

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00199204

Keywords

Search

Navigation